Hansa Biopharma, “Hansa”, today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of ...
LUND, Sweden , Dec. 7, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback